Inhaled nebulized Budesonide.

Phase 1Small molecule

Inhaled nebulized Budesonide. is one of 8 small molecule programs targeting Acute Bronchiolitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute BronchiolitisActive, not recruiting

Acute BronchiolitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Acute Bronchiolitis

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

3 2

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

1 3

Adrenaline

AARS Pharmaceuticals, Inc.

Phase 3

1 4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 2

1 5

Singulair

AstraZeneca

Preclinical

1 6

Singulair

OOrganon and Co

Preclinical

1 7

Inhaled nebulized Budesonide.

AAssiut University

Phase 1

1 8

Dexamethasone 12

AAssiut University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Bronchiolitis1 trial

Steroid Therapy in Acute Bronchiolitis A New Old Line of Therapy.

Unknown status·—·Phase 1·NCT03436225·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Inhaled nebulized Budesonide.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inhaled nebulized Budesonide. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inhaled nebulized Budesonide.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assiut University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAssiut University

Inhaled nebulized Budesonide.

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Bronchiolitis1 trial

References

Drug Info

Quick Facts

Related News